



UCB's shareholder meeting today

- For 2013: Gross dividend + 2% of € 1.04 per share payable May 5
- Outlook 2014 confirmed

Brussels (Belgium), 24 April 2014 – 18:00 (CEST) – Today, UCB held its Annual General Meeting (AGM) and Extraordinary General Meeting (EGM). At the Annual General Meeting 142.8 million shares (74.75% of shares outstanding) were represented. During the course of this meeting, Roch Doliveux, Chief Executive Officer UCB and Jean-Christophe Tellier, Chief Executive Officer-Elect and Chairman of the Executive Committee, gave the shareholders of UCB an overview of UCB's strategic growth priorities, the financial year 2013 and the first three months of 2014, and confirmed the financial outlook for 2014. The speech is available on the company's website:
<http://www.ucb.com/investors/Governance/Shareholders-meeting>

The AGM approved for the fiscal year 2013 the payment of a gross dividend of € 1.04 per share (net dividend of € 0.78 per share) compared with € 1.02 per share for 2012 (net € 0.765). The ex-dividend day is 29 April 2014, the dividend (coupon no. 17) will be payable on 5 May 2014.

The AGM appointed Cédric van Rijckevorsel and Jean-Christophe Tellier as Directors, and Kay Davies as Independent Director. For curriculum vitae of the new Board members, please visit UCB website:
<http://www.ucb.com/investors/Governance/Corporate-governance>

Also all other agenda items put to vote were approved by the shareholders represented. For details please visit UCB's website: <http://www.ucb.com/investors/Governance/Shareholders-meeting>

At the EGM, all agenda items put to vote were approved by the shareholders represented. For details, please see: <http://www.ucb.com/investors/Governance/Shareholders-meeting>

The Annual Report 2013 of UCB is available on UCB's website:
<http://www.ucb.com/investors/Financials/Financial-reports/Annual-reports>

The interim report on the first three months 2014 has been published today, the financial results for the first half year 2014 will be announced on 30 July 2014 and an interim report for the first nine months of 2014 is due on 24 October 2014.

Next year's AGM will be held on 30 April 2015 in Brussels (Belgium).

For further information

Investor Relations

Antje Witte, Investor Relations, UCB
T +32 2 559 94 14, antje.witte@ucb.com

Corporate Communications

France Nivelles, Global Communications, UCB
T +32.2.559.9178, france.nivelles@ucb.com

Alexandra Deschner, Investor Relations, UCB
T +32 2 559 96 83, alexandra.deschner@ucb.com

Laurent Schots, Media Relations, UCB
T +32.2.559.9264, laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 8 700 people in approximately 40 countries, the company generated revenue of €3.4 billion in 2013. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.